[{"uuid": "d516efb0-513d-3536-bea5-ed4090110d50", "title": "Biomea Fusion to Become a Diabetes & Obesity Medicines Company", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biomea-fusion-become-diabetes-obesity-140000847.html", "providerPublishTime": 1736776800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/SjN7sW6KWrRbGV9yW2csuQ--~B/aD04MTQ7dz0zMDU4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 3058, "height": 814, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/spVSeVntoYC3Guj1krmskQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMEA"]}, {"uuid": "a0657e3a-f2fe-32b8-a1d6-977208a77bec", "title": "Here\u2019s Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-biomea-fusion-inc-nasdaq-140410603.html", "providerPublishTime": 1736172250, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/rc33b3QWKFbOJEjYacTUCw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/a3eb6b253987ff6de821a395fc8b397a", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/MZBOFF3XBTYgMrqia2CeuQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/a3eb6b253987ff6de821a395fc8b397a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMEA"]}, {"uuid": "60471d9f-a40e-30db-aa60-a865b5a55cc0", "title": "3 US Penny Stocks With Market Caps Up To $2B", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/3-us-penny-stocks-market-131117621.html", "providerPublishTime": 1736428277, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/jg8PADlkEXYEw5CXkVJkoA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/064d0b7911046f8efd85160776a9b33b", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ORG9roy7DaPbo0dPcdDS6A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/064d0b7911046f8efd85160776a9b33b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["INTR", "BMEA", "SY"]}, {"uuid": "851e128b-3902-3949-b4b9-9abe12f9e8a2", "title": "Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biomea-fusion-present-43rd-annual-120000705.html", "providerPublishTime": 1736164800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/SjN7sW6KWrRbGV9yW2csuQ--~B/aD04MTQ7dz0zMDU4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 3058, "height": 814, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/spVSeVntoYC3Guj1krmskQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMEA"]}, {"uuid": "a112ac79-e70f-35da-98a2-3d4663bc7ffe", "title": "Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biomea-fusion-reports-preclinical-data-140000259.html", "providerPublishTime": 1736258400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/SjN7sW6KWrRbGV9yW2csuQ--~B/aD04MTQ7dz0zMDU4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 3058, "height": 814, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/spVSeVntoYC3Guj1krmskQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMEA"]}, {"uuid": "d2aef220-48e3-35f8-b276-c8804be8825f", "title": "Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?", "publisher": "Benzinga", "link": "https://finance.yahoo.com/news/why-diabetes-drug-developer-biomea-154109548.html", "providerPublishTime": 1734450069, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/4r1ASjjN9k9MVF2vjRzbvg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/3bf1a938df0d3f89190bfb6277268ae3", "width": 983, "height": 553, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/VcKSvzUb.OaOTN9z4pb09A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/3bf1a938df0d3f89190bfb6277268ae3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMEA"]}, {"uuid": "e8b1e39c-3ee6-3f8b-87f8-94101a7e6150", "title": "Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/biomea-fusion-reports-preliminary-data-224356552.html", "providerPublishTime": 1733784236, "type": "STORY", "relatedTickers": ["BMEA"]}, {"uuid": "d5f9666d-5b09-3c13-8e48-43260250e4eb", "title": "Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biomea-fusion-host-conference-call-231500658.html", "providerPublishTime": 1734390900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/SjN7sW6KWrRbGV9yW2csuQ--~B/aD04MTQ7dz0zMDU4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 3058, "height": 814, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/spVSeVntoYC3Guj1krmskQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMEA"]}, {"uuid": "39ebc22c-378e-375a-b4aa-a856f010d8d6", "title": "Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biomea-fusion-host-conference-call-130000739.html", "providerPublishTime": 1733490000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/SjN7sW6KWrRbGV9yW2csuQ--~B/aD04MTQ7dz0zMDU4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 3058, "height": 814, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/spVSeVntoYC3Guj1krmskQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMEA"]}, {"uuid": "5e7617c2-7961-3628-97d5-63df726a8025", "title": "Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biomea-fusion-announces-positive-topline-131000872.html", "providerPublishTime": 1734441000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/SjN7sW6KWrRbGV9yW2csuQ--~B/aD04MTQ7dz0zMDU4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 3058, "height": 814, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/spVSeVntoYC3Guj1krmskQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMEA"]}, {"uuid": "774370a2-0059-3424-a6dc-c545e8ba1adf", "title": "Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biomea-fusion-announces-oral-poster-220200123.html", "providerPublishTime": 1734040920, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/SjN7sW6KWrRbGV9yW2csuQ--~B/aD04MTQ7dz0zMDU4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 3058, "height": 814, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/spVSeVntoYC3Guj1krmskQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMEA"]}, {"uuid": "f5246027-1fa0-3860-bf4c-8fa00a3ee637", "title": "Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/biomea-fusion-inc-reports-inducement-210500985.html", "providerPublishTime": 1733173500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/SjN7sW6KWrRbGV9yW2csuQ--~B/aD04MTQ7dz0zMDU4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 3058, "height": 814, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/spVSeVntoYC3Guj1krmskQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/b4671cf05b5be2ee4acb607d886beaf2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMEA"]}]